Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Neurofibrosarcoma 1Melanoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Carcinoma, Basal Cell 1

Interventions

Doxorubicin 5pembrolizumab 4Specimen Handling 4Radiotherapy 4Radiation 4Nivolumab 4Magnetic Resonance Spectroscopy 3Ipilimumab 3CTLA-4 Antigen 3Biopsy 3cabozantinib 2Ifosfamide 2tremelimumab 1talimogene laherparepvec 1regorafenib 1peposertib 1pazopanib 1olaratumab 1liposomal doxorubicin 1futibatinib 1fludarabine 1eribulin 1durvalumab 1avelumab 1aldesleukin 1X-Rays 1Trabectedin 1Standard of Care 1Quality of Life 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × BO-112 × 1 year × Clear all
NCT04420975 2026-03-10

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
14 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡